(PDF) MA10.08 Choice of Taxane and Outcomes in the

MA10.08 Choice of Taxane and Outcomes in the KEYNOTE-407 Study of Pembrolizumab Plus Chemotherapy for Metastatic Squamous NSCLC

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.400

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

Pcn34 - Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-Squamous NSCLC – A Network Meta-Analysis

Value in Health

Occupational Health

English

P1.01-09 Pembrolizumab Plus Ipilimumab or Placebo in 1L Metastatic NSCLC With PD-L1 Tumor Proportion Score (TPS) ≥50%: KEYNOTE-598

Journal of Thoracic Oncology

Respiratory Medicine

English

PD.1.01 Health-Related Quality of Life With Pembrolizumab or Placebo + Pemetrexed + Platinum in Non-Squamous NSCLC: KEYNOTE-189

Journal of Thoracic Oncology

Respiratory Medicine

English

CHFR Protein Expression Predicts Outcomes to Taxane-Based First Line Therapy in Metastatic NSCLC

Clinical Cancer Research

Cancer Research

English

Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy for Previously Untreated Metastatic Non-Small Cell Lung Cancer in the USA

English

P1.01-106 Pembrolizumab Randomized, Phase 1 Study in Chinese Patients With Advanced NSCLC: KEYNOTE-032

Journal of Thoracic Oncology

Respiratory Medicine

English

Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Nonsquamous Non-Small-Cell Lung Cancer: A Network Meta-Analysis

English

P1.01-52 BR-34- Randomized Trial of Durvalumab and Tremelimumab +/- Platinum Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-81 Phase 3 Study of Pemetrexed-Platinum With or Without Pembrolizumab for TKI-Resistant/EGFR-Mutated Advanced NSCLC: KEYNOTE-789

Journal of Thoracic Oncology

Respiratory Medicine

English